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Background
Since HIV transmits primarily via mucosal route during
sexual transmission; an ideal HIV-1 vaccine should induce
both systemic and mucosal humoral and cellular
responses. Although HIV envelope formulated with QS21
or Alum elicits strong systemic antibody responses,
mucosal antibody and T-cell responses are generally weak.
Herein we examined the systemic and mucosal immune
responses elicited following a DNA prime/protein boost
HIV vaccine formulated with inulin-derived (Advax) adju-
vants. Such adjuvants have been shown to be less reac-
togenic and can induce immune responses in systemic
and mucosal compartments.
Methods
BALB/c mice were primed with plasmid DNA encoding
HIV Env BaL by intramuscular route (IM) at week 0, 2 and
4 and boosted with gp120 protein formulated with differ-
ent Advax adjuvants administered via IM or intranasal
(IN) at week 9 and 11 either alone or in combination.
Results
Immunization with gp120 formulated in Advax-M adju-
vant by IN route elicited anti-Env antibodies in serum and
mucosal secretions including vaginal washes, fecal pellets,
lung washes and saliva and this response was significantly
enhanced in DNA primed animals. Although IgA antibod-
ies were detected in mice immunized systemically with
Advax-P adjuvant, levels were lower than that observed
with Advax-M adjuvant. Use of both adjuvants where
mice were immunized with gp120 formulated with
Advax-M by IN route followed by Advax-P adjuvant by IM
route or vise versa also elicited strong IgA responses in sys-
temic and mucosal compartments persisting for a pro-
longed period. Robust induction of Th1 cytokines was
noted following DNA prime/protein boost immunization
as compared to protein only immunization with Advax-M
or with the combination adjuvant approach.
Conclusion
These findings demonstrate that the DNA prime/protein
boost vaccine strategy for HIV using inulin-based adju-
vants elicits immune responses in systemic and mucosal
compartments, thereby providing broad immunological
responses for the protective efficacy against mucosal trans-
mission of HIV-1.
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